Mildronate solution for intravenous injection 0.5g/5ml in ampoules 5ml №5×2

Name:
Mildronate.
Description:
The solution for i / m, i / v and parabulbar administration is transparent, colorless. The main active ingredient is Meldonium. Release form Solution. Dosage 5 ml. Many years of experience in the treatment of acute myocardial infarction and unstable angina pectoris in cardiology departments shows that Mildronate® is not a first-line drug for acute coronary syndrome and its use is not urgently needed. Since January 1, 2016, meldonium has been included in the list of banned substances of the World Anti-Doping Agency. Influence on the ability to drive vehicles and control mechanisms There is no evidence of an adverse effect of the drug Mildronate® on the speed of the psychomotor reaction. Pharmacological action Meldonium is a structural analogue of gamma-butyrobetaine, a substance found in every cell of the human body. Under conditions of increased load, Mildronate® restores the balance between the delivery and demand of cells for oxygen, eliminates the accumulation of toxic metabolic products in cells, protecting them from damage; also has a tonic effect. As a result of its use, the body acquires the ability to withstand the load and quickly restore energy reserves. Due to these properties, Mildronate® is used to treat various disorders of the cardiovascular system, blood supply to the brain, as well as to increase physical and mental performance. As a result of a decrease in the concentration of carnitine, gamma-butyrobetaine, which has vasodilating properties, is intensively synthesized. In the case of acute ischemic myocardial injury, Mildronate® slows down the formation of a necrotic zone and shortens the rehabilitation period. In heart failure, it increases myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral circulation, Mildronate® improves blood circulation in the focus of ischemia, promotes the redistribution of blood in favor of the ischemic area. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism with withdrawal syndrome. Pharmacokinetics The bioavailability of the drug after intravenous administration is 100%. Cmax in blood plasma is achieved immediately after its administration. It is metabolized in the body with the formation of two main metabolites, which are excreted by the kidneys. T1 / 2 is 3-6 hours. Indications for use – in the complex therapy of coronary artery disease (angina pectoris, myocardial infarction); – chronic heart failure; – dishormonal cardiomyopathy; – in the complex therapy of acute and chronic disorders of the blood supply to the brain (stroke and cerebrovascular insufficiency); – hemophthalmos and retinal hemorrhages of various etiologies; – thrombosis of the central retinal vein and its branches; – retinopathy of various etiologies (diabetic, hypertensive); – reduced performance; – mental and physical overstrain (including athletes); – withdrawal syndrome in chronic alcoholism (in combination with specific alcoholism therapy). Dosage and administration In view of the possible development of a stimulating effect, it is recommended to apply in the first half of the day. Mildronate® is prescribed intramuscularly, intravenously and parabulbarno. The route of administration, doses and duration of treatment are set individually, depending on the indications, the severity of the condition and other factors. With coronary artery disease (myocardial infarction), as part of complex therapy, the drug is prescribed intravenously in a stream of 0.5-1.0 g / day (5-10 ml of Mildronate®), using the entire dose at once or dividing it into 2 injections. In IHD (stable angina pectoris), chronic heart failure and dyshormonal cardiomyopathy as part of complex therapy, the drug is prescribed intravenously in a stream of 0.5-1.0 g / day (5-10 ml of Mildronate®), using the entire dose at once or dividing it into 2 injections , or / m 0.5 g 1-2 times / day, the course of treatment is 10-14 days, followed by the transition to taking the drug inside. The general course of treatment is 4-6 weeks. As part of the complex therapy of cerebrovascular accidents in the acute phase, the drug is prescribed at 0:5 g (5 ml of Mildronate®) 1 time / day intravenously for 10 days, followed by the transition to oral administration of 0.5-1 g. General course treatment – 4-6 weeks. In chronic cerebrovascular insufficiency (dyscirculatory encephalopathy), 0.5 g (5 ml of Mildronate®) is prescribed intramuscularly or intravenously 1 time / day for 10 days, then 0.5 g orally. The general course of treatment is 4-6 weeks. Repeated courses (usually 2-3 times a year) are possible after consultation with a doctor. With hemophthalmos and retinal hemorrhages of various etiologies, thrombosis of the central retinal vein and its branches, retinopathy of various etiologies (diabetic, hypertensive), 0.05 g (0.5 ml of Mildronate®) is prescribed parabulbarno for 10 days. The drug is used as part of combination therapy. With mental and physical overstrain, the drug is administered at 0.5 g (5 ml of Mildronate®) intramuscularly or intravenously 1 time / day. The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2-3 weeks. In chronic alcoholism, 0.5 g (5 ml of Mildronate®) is prescribed intramuscularly or intravenously 2 times / day. The course of treatment is 7-10 days. Use during pregnancy and lactation The safety of use in pregnant women has not been studied, therefore, in order to avoid possible adverse effects on the fetus, its use is contraindicated. The excretion of the drug Mildronate® with breast milk and its effect on the health of the newborn have not been studied. If necessary, the use of the drug during lactation should stop breastfeeding. Precautions With caution, the drug should be prescribed for liver diseases. With caution, the drug should be prescribed for kidney disease. Contraindicated in patients under the age of 18 years, tk. efficacy and safety have not been established. Interaction with other drugsMildronate® can be combined with antianginal agents, anticoagulants, antiplatelet agents, antiarrhythmic agents, diuretics, bronchodilators. The drug enhances the action of cardiac glycosides. In view of the possible development of moderate tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-blockers, other antihypertensive drugs and peripheral vasodilators, because. Mildronate® enhances their action. Contraindications – increased intracranial pressure (in violation of venous outflow, intracranial tumors); – age up to 18 years (efficacy and safety have not been established); – pregnancy; – the period of breastfeeding; – Hypersensitivity to the components of the drug. With caution: in diseases of the liver and / or kidneys. Composition 1 ml 1 amp. meldonium dihydrate 100 mg 500 mg Excipients: water for injection. Overdose Mildronate® has low toxicity and does not cause side effects dangerous to the health of patients. Symptoms: decrease in blood pressure, accompanied by headache, tachycardia, dizziness and general weakness. Treatment: symptomatic therapy. Side effects Depending on the frequency of occurrence, the following groups of undesirable adverse reactions according to WHO are distinguished: very often (> 1/10), often (> 1/100, <1/10), infrequently (> 1/1000, <1/100), rarely (>1/10,000 and <1/1000), very rarely (<1/10,000), the frequency is unknown (it is impossible to estimate the frequency from the available data). Allergic reactions: rarely - redness, rashes, itching, swelling. From the side of the cardiovascular system: rarely - tachycardia, a decrease or increase in blood pressure. From the digestive system: rarely - dyspeptic phenomena. Others: rarely - arousal; very rarely - eosinophilia, general weakness. Storage conditions The drug should be stored out of the reach of children at a temperature not exceeding 25 ° C; do not freeze. Buy Mildronate solution for intravenous injection 0.5g/5ml in ampoules 5ml No. 5x2 Price for Mildronate solution for intravenous injection 0.5g/5ml in ampoules 5ml No. 5x2 /5ml in ampoules 5ml №5x2